Literature DB >> 3893842

Discrepancies between pharmacokinetic studies of amitriptyline.

P Schulz, P Dick, T F Blaschke, L Hollister.   

Abstract

In this article, studies on the disposition of amitriptyline after administration of a single dose, as well as following long term administration are reviewed. While long term studies showed bias towards a higher mean apparent oral clearance, studies in normal subjects nevertheless indicated a higher apparent oral clearance than that calculated from steady-state concentrations in depressed patients. Methodological issues could account for some of the discrepancies in mean values of the pharmacokinetic parameters of amitriptyline. Broad individual variability in the elimination rate of amitriptyline has been confirmed but could not be attributed to the clinical characteristics of the subjects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893842     DOI: 10.2165/00003088-198510030-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  39 in total

1.  Plasma levels of a new pelletized form of amitriptyline for maintenance therapy.

Authors:  H B Hucker; S C Stauffer; F G Clayton; B R Nakra; R Gaind
Journal:  J Clin Pharmacol       Date:  1975 Feb-Mar       Impact factor: 3.126

2.  [Determination of the plasma concentration and antidepressive effect of amitriptyline].

Authors:  R Volmat; P Bechtel; G Allers; B Vandel; S Vandel
Journal:  Therapie       Date:  1977 May-Jun       Impact factor: 2.070

3.  Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.

Authors:  S Vandel; B Vandel; M Sandoz; G Allers; P Bechtel; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

4.  Plasma and erythrocyte levels of tricyclic antidepressants in depressed patients.

Authors:  M Linnoila; F Dorrity; K Jobson
Journal:  Am J Psychiatry       Date:  1978-05       Impact factor: 18.112

5.  Elimination and pharmacological effects following single oral doses of 50 and 75 mg of amitriptyline in man.

Authors:  P Schulz; A E Balant-Gorgia; A Kubli; C Gertsch-Genet; G Garrone
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1983

6.  Binding of tricyclic antidepressants and perazine to human plasma. Methodology and findings in normals.

Authors:  M Brinkschulte; U Breyer-Pfaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-07       Impact factor: 3.000

7.  Reduced levels of tricyclic antidepressants in plasma from Vacutainers.

Authors:  D J Brunswick; J Mendels
Journal:  Commun Psychopharmacol       Date:  1977

8.  Pharmacokinetics of amitriptyline infused intravenously in man.

Authors:  A Jorgensen; V Hansen
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

9.  On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients.

Authors:  G Jungkunz; H J Kuss
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1980-05

10.  Pharmacokinetics of amitriptyline in the elderly.

Authors:  J F Henry; C Altamura; R Gomeni; M P Hervy; F Forette; P L Morselli
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1981-01
View more
  13 in total

1.  Urinary metabolites of amitriptylinoxide and amitriptyline in single-dose experiments and during continuous therapy.

Authors:  B Becher; W Fischer; Z Taneri; E Scholz; W E Müller; U Breyer-Pfaff
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Average parameters in bioavailability studies: an application to slow-release amitriptyline formulation.

Authors:  P Fagiolino; M Vázquez; E Savio; L Domínguez; J M Aiache; E Beyssac
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

3.  Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline.

Authors:  S H Jo; J B Youm; C O Lee; Y E Earm; W K Ho
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 4.  Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.

Authors:  C Sánchez; J Hyttel
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 5.  Pharmacokinetic interactions of topiramate.

Authors:  Meir Bialer; Dennis R Doose; Bindu Murthy; Christopher Curtin; Shean-Sheng Wang; Roy E Twyman; Stefan Schwabe
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Low concentrations of amitriptyline inhibit nicotinic receptors in unmyelinated axons of human peripheral nerve.

Authors:  A Freysoldt; J Fleckenstein; P M Lang; D Irnich; P Grafe; R W Carr
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

7.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 8.  Pharmacokinetics of antidepressants in patients with hepatic impairment.

Authors:  Massimo Carlo Mauri; Alessio Fiorentini; Silvia Paletta; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

9.  Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice.

Authors:  F Coudore; J Fialip; A Eschalier; J Lavarenne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jan-Mar       Impact factor: 2.441

10.  Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data.

Authors:  Shufan Ge; Yifan Tu; Ming Hu
Journal:  Curr Pharmacol Rep       Date:  2016-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.